Educational Symposium
Management of RAAS Inhibitor Therapy After Hyperkalemia in Patients with CKD and Heart Failure
November 08, 2025 | 12:45 PM - 01:45 PM
Location: Lanier Grand Ballroom D, Hilton Americas-Houston
Session Description
Patients with CKD and heart failure are at risk for life-threatening hyperkalemia. This symposium reviews RAAS inhibitor therapy after hyperkalemia in patients with CKD and heart failure. Management options are extensively discussed, including dietary and medical therapies. Special attention is paid to the role of potassium binders in this patient population.
Support is provided by an educational grant from AstraZeneca.
Learning Objective(s)
- Explain the incidence and scope of hyperkalemia in the setting of CKD and heart failure
- Describe the management of hyperkalemia in the setting of CKD and heart failure
Learning Pathway(s)
- CKD Non-Dialysis
- Fluid‚ Electrolyte‚ and Acid-Base Disorders
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Clinical Impact of Suboptimal RAAS Inhibitor Therapy After Hyperkalemia
12:55 PM - 01:15 PM
- Management of Hyperkalemia and RAAS Inhibitors
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM